Epithelioid sarcoma
Revision as of 11:18, 26 July 2022 by Warner-admin (talk | contribs) (Text replacement - "{| class="wikitable" style="float:right; margin-left: 5px;" |- |back to top |}" to "")
| Section editor | |
|---|---|
 |
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN  ejdavis25
|
Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
1 regimens on this page
1 variants on this page
|
All lines of therapy
Tazemetostat monotherapy
Regimen
| FDA-recommended dose |
| Study | Years of enrollment | Evidence |
|---|---|---|
| Gounder et al. 2020 (EZH-202) | 2015-2017 | Phase 2 (RT) |
Biomarker eligiblity criteria
One or both of the following:
- Loss of INI1 expression by IHC
- Biallelic SMARCB1 alterations
Targeted therapy
- Tazemetostat (Tazverik) 800 mg PO twice per day
28-day cycles
References
- EZH-202: Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 Nov;21(11):1423-1432. Epub 2020 Oct 6. link to original article contains protocol PubMed NCT02601950